Department of Medicine, University of Arkansas for Medical Sciences, Central Arkansas Veterans Healthcare System, Little Rock, AR, USA.
Curr Atheroscler Rep. 2011 Feb;13(1):57-63. doi: 10.1007/s11883-010-0140-5.
The role of statins in the treatment and prevention of cardiovascular diseases, such as coronary artery disease, acute coronary syndromes, diabetes, or stroke, is well established. However, there are still some questions regarding the role of statins in patients with chronic kidney disease (CKD). Dyslipidemia is a known cardiovascular risk factor in individuals without CKD. In these patients, however, the relation of dyslipidemia to cardiovascular risk is complex, and the underlying pathobiological mechanisms are complex. Statins have proven to be highly effective in patients with initial stages of CKD; however, their effects in patients with advanced-stage CKD have been neutral despite a low-density lipoprotein cholesterol-lowering effect. In this review, we summarize the findings of the recent clinical trials of statins in renal disease and make recommendations for our patients.
他汀类药物在治疗和预防心血管疾病（如冠心病、急性冠脉综合征、糖尿病或中风）中的作用已得到充分证实。然而，关于他汀类药物在慢性肾脏病（CKD）患者中的作用仍存在一些疑问。血脂异常是无 CKD 个体已知的心血管危险因素。然而，在这些患者中，血脂异常与心血管风险的关系很复杂，潜在的病理生物学机制也很复杂。他汀类药物在 CKD 早期患者中已被证明非常有效；然而，尽管它们具有降低低密度脂蛋白胆固醇的作用，但在晚期 CKD 患者中的效果却是中性的。在这篇综述中，我们总结了他汀类药物在肾脏病中的最新临床试验结果，并为我们的患者提出了建议。
